ArticleFrontiers in pharmacology2026
Comparative pharmacokinetics of total ginsenosides between young and aging mice.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ginsenosides, the primary bioactive constituents of ginseng, are widely recognized as popular natural products with anti-aging properties. However, they generally exhibit poor oral bioavailability. Moreover, existing pharmacokinetic studies have predominantly focused on young animal models, leaving a critical gap in understanding how aging alters the absorption, distribution, metabolism, and excretion of these compounds. This study aims to elucidate the multi-component pharmacokinetics and tissue distribution profiles of total ginsenosides following oral administration in both young and aging mice. Methods: The validity of the aging mouse model was first confirmed through a series of physiological evaluations. A multiple reaction monitoring (MRM) technique was then employed to conduct comparative pharmacokinetic and tissue distribution analyses of 15 targeted ginsenosides after oral administration in young and aging mice. Results: Aging mice exhibited significantly higher systemic exposure (AUC) and markedly reduced clearance rates compared to their young counterparts. Tissue distribution analysis revealed the highest accumulation of ginsenosides in the liver, followed by the heart, kidneys, spleen, lungs, testes, and brain, confirming the liver as the primary metabolic site. Discussion: These findings demonstrate that aging increases systemic exposure, prolongs half-lives, and enhances tissue accumulation of ginsenosides. This study provides essential scientific evidence for the rational clinical application and dosage optimization of ginseng in aging populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.